• pressReleases
  • newsMedia
  • Career Openings
  • News & Press

    Press Releases

    Keyword search
    Abbisko Therapeutics Announces Dosing of First Patient in A Phase I Clinical Study of ABSK043 In Australia
    Sep 03,2021
    Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK043 in Australia
    Jul 12,2021
    Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
    Jul 05,2021
    Abbisko Therapeutics Announces Dosing of First Patient in A Phase Ib Clinical Study of ABSK011 In China
    Jun 29,2021
    Abbisko Therapeutics Announces the Appointment of Mr. Yongyi Li as General Counsel
    Jun 04,2021
    Abbisko Therapeutics Announces the Appointment of Ms. Jia Feng as Executive Director and Head of Human Resource
    Jun 04,2021
    Abbisko Therapeutics and AstraZeneca China Announce Strategic Partnership
    May 25,2021
    Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
    Apr 29,2021
    Abbisko Therapeutics Announces the Appointment of Dr. Zhen Zhang as CMC VP
    Apr 19,2021
    Abbisko Therapeutics Announces the Appointment of Dr. Jing Ji as Chief Medical Officer
    Feb 18,2021
    Abbisko Therapeutics Featured at the 39th Annual J.P. Morgan Healthcare Conference
    Jan 19,2021
    Abbisko Therapeutics Announces the Appointment of Dr. Xie Kewei as Chief Business Officer
    Jan 12,2021
    Abbisko Therapeutics Announces the Completion of $123 Million Series D Financing Led by The Carlyle Group
    Jan 08,2021
    Abbisko Therapeutics Announces the Appointment of Mr. Ye Lin as Chief Financial Officer
    Nov 16,2020
    Abbisko Therapeutics Obtained ABSK021 IND Approval in China
    Oct 29,2020
    Abbisko Therapeutics Obtained IND approval for Phase 1b/II Clinical Trial of Mavorixafor in Combination with Toripalimab in China
    Sep 09,2020
    Abbisko Therapeutics Announces $70M Series C Financing Led by Temasek
    Mar 25,2020
    Abbisko Therapeutics Announces Receiving of the IND Approval by the China NMPA for ABSK-011, A Novel FGFR4 Inhibitor
    Mar 09,2020
    Abbisko Therapeutics Announces the IND Approval of a Novel FGFR4 Inhibitor ABSK011 by the Taiwan FDA
    Dec 06,2019
    Abbisko Therapeutics Announces Initiation of Phase 1 Trial for ABSK021, its Selective CSF-1R Small Molecule Inhibitor
    Aug 19,2019
    X4 Pharmaceuticals and Abbisko Therapeutics Enter into Oncology Development and Commercialization Agreement for Mavorixafor in Greater China
    Jul 17,2019
    Abbisko Therapeutics Wins the Zhangjiang Science City Innovation & Progress Award for Outstanding Enterprises
    Jan 18,2019
    Abbisko Therapeutics is Awarded as One of the Most Promising Enterprises Founded by Foreign-educated Returnees
    Dec 23,2018
    Shanghai Mayor Ying Yong Presents Abbisko Therapeutics with “MNC’s R&D Centers” Certificate
    Dec 07,2018
    Dr. Hongping Yu Attends and Delivers a Speech at ACS Conference
    Oct 28,2018
    Abbisko Wins the Best Biomedical Investment Case Award in the Healthcare Investment Rankings 2018
    Mar 30,2018
    Dr. Yao-chang Xu Attends the Hong Kong Biotech Summit 2018
    Mar 23,2018
    Dr. Yao-chang Xu Presents at the BIO Asia International Conference
    Mar 21,2018
    Dr. Zhui Chen Attends China Healthcare Investment & Partnering Symposium 2018 on Invitation
    Mar 16,2018
    Dr. Yao-chang Xu Attends Zhangjiang League of Makers Health Industry Association’s Inauguration
    Nov 20,2017
    Dr. Yao-chang Xu Gives a Lecture at Peking University Clinical Research Institute
    Apr 06,2017
    Abbisko Completes Series A Round Financing of $ 28 Million
    Feb 05,2017
    Dr. Hongping Yu Attends a Teach-in at Nankai University on Invitation
    Nov 24,2016
    Dr. Yao-chang Xu Attends Bank of America Merrill Lynch China Annual Conference 2016 and Delivers a Speech
    Nov 01,2016

    Tel:(+86) 021-68912098

    E-Mail:Public@abbisko.com Bd@abbisko.com

    Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1